Top Injectable Manufacturer in Oman – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 4 hours ago
- 10 min read
Last Updated: August 25, 2026
TL;DR: Oman is a high-maturity Gulf market with a regulator that is publishing its rulebook in the open. Medicines are handled by the Drug Safety Center of the Ministry of Health – the current body, replacing the older Directorate General naming that still circulates in secondary commentary – which registers first the company and then the product, entirely through the Ministry's e-portal, with a Technical Committee for Registration and Prices taking the decision and setting the price. Registration requires an Omani commercial agency certificate and a licensed pharmaceutical warehouse, so a local partner is not optional. Products already registered through the Gulf Health Council's central registration route are fast-tracked, and GCC barcoding specifications require GS1 DataMatrix carrying GTIN, expiry, batch and serial number. Farbe Firma Pvt Ltd manufactures sterile injectables on ISO Class 5 aseptic lines in a WHO-GMP certified facility in Gujarat, India, and builds Omani files with hot-and-humid Zone IV stability, serialisation-ready artwork and full GMP evidence.
Key Takeaways
Get the regulator's name right, because it signals whether your partner is current. Oman's medicines regulator is the Drug Safety Center (DSC) of the Ministry of Health, which is the name under which the Ministry publishes its guidelines, circulars and public consultations in 2025 and 2026. A good deal of legal commentary still refers to a Directorate General of Pharmaceutical Affairs and Drug Control; that naming is out of date. The DSC operates a two-tier model – registration of the medicinal company or site first, then a Marketing Authorization Application per product – with both submitted through the Ministry's e-portal, and with a Technical Committee for Registration and Prices approving, rejecting or ordering an inspection, and setting the approved price.
A licensed Omani agent is a hard prerequisite, not a commercial preference. The Ministry of Health's own service listing for registering health products requires the applicant to hold a pharmaceutical warehouse licence issued by the Directorate of Pharmaceutical Licences, a commercial agency certificate from the Ministry of Commerce and Industry, and a commercial register entry. The published service completion period is 360 working days and the listed fee is 240 per product. A foreign manufacturer therefore appoints and equips a local agent-distributor before a product file can even be opened, which makes the quality and completeness of the documentation you hand that agent the decisive factor in how the file moves.
The GCC route is the real accelerator, and it is written into Oman's own framework. The Gulf Central Committee for Drug Registration, established by resolution at the 45th conference in Geneva in May 1998, registers companies and products under unified GCC regulations and its mandate explicitly includes inspecting manufacturing sites for GMP compliance. In the framework the Drug Safety Center put out for public consultation in 2026, products already registered through the Gulf Health Council route are placed on a fast-track assessment pathway, and a company file submitted on the basis of GCC central registration has its validity aligned to the GCC certificate. Building one GCC-grade file is therefore worth more than building six national ones.
Serialisation and Arabic labelling are packaging decisions you make before you quote. The Gulf Health Council's drug barcoding specification, published on the Omani Ministry's own Drug Safety Center page, requires a move from linear barcodes to GS1 DataMatrix carrying at minimum a GTIN, expiry date, batch or lot number and a serial number of up to twenty alphanumeric characters, and it applies to international manufacturers exporting to the GCC as well as to GCC manufacturers. On labelling, the Drug Safety Center's guideline requires an Arabic translation of outer packaging information for all medicines except those intended solely for hospital use, mandates distinct colour coding between strengths, and sets reduced particulars for small immediate containers of ten millilitres or less – which is exactly the ampoule and vial format most injectables ship in.
Introduction: Why Oman Demands a Premium Injectable Manufacturer in Oman
Oman is not a market you enter opportunistically. It is import-dependent – India's Press Information Bureau, summarising the India-Oman economic partnership, describes the Omani pharmaceutical market as valued at about US$302.84 million in 2024 and projected to reach US$473.71 million by 2031 at a compound annual growth rate of 6.6%, and notes explicitly that the market remains heavily import-dependent – but it is also a market where the buyer is sophisticated, the regulator publishes, and the paperwork is checked. The Ministry of Health's Directorate General of Medical Supplies is the authorised body for supplying all Ministry health institutions with medicines, surgical and laboratory materials, and it is explicitly responsible for qualifying medical materials companies to take part in Ministry tenders under the pre-qualification regulations issued as Ministerial Decision No. 109/2008.
What is unusual, and genuinely helpful to an exporter, is how much of the demand picture Oman publishes. The Directorate General of Medical Supplies puts out tender price lists and three-year average annual consumption data by category – pharmaceuticals, vaccines and sera for 2025, renal dialysis items for 2024, respiratory and anaesthesia items for 2025, cardiac items for 2026, ophthalmology and laboratory consumables – alongside guidelines for health technology assessment. A manufacturer can therefore benchmark realistic prices and volumes before bidding instead of guessing. Choosing an injectable manufacturer in Oman's supply chain means choosing one that will actually read those lists, price against them, and commit to the batch sizes and delivery schedules a centrally tendered hospital system needs.
What Sets a World-Class Injectable Manufacturer in Oman Apart
The first thing that separates a credible partner here is knowing which parts of the rulebook are settled and which are still in consultation. Through 2026 the Drug Safety Center has run public consultations on a substantial set of guidelines at once: the overall regulatory framework for company and product approval, withdrawal and suspension of marketing authorisations, registration by verification and abridged pathways, variations, labelling and product information, conditional approval and emergency use, BCS-based biowaivers, and eCTD preparation and submission. The framework document proposes a reliance model – fast-track assessment for products approved by a stringent regulatory authority, for vaccines with WHO prequalification, for first and second generics, for locally manufactured products and for GCC-registered products – along with a possible GMP inspection waiver where a reference authority has inspected within the last two years. Those are proposals under consultation, not settled Omani law, and a supplier who presents them to you as guaranteed entitlements is overselling. The one officially published figure is the Ministry's service catalogue entry of 360 working days.
The second is being built for the Gulf rather than adapted to it. Oman applies the GCC variation guideline in its published version, references the GCC regulatory framework for drug approval and the GCC stability guidelines, and the framework under consultation calls for stability generated under Zone IV hot and humid tropical conditions in modules two and three, with module one meeting eCTD requirements. The Gulf Health Council additionally runs a central registration portal and a joint procurement programme, and operates a Gulf committee for pharmaceutical pricing whose published remit includes re-pricing at the five-yearly re-registration point and standardising export prices by therapeutic group. A manufacturer whose stability programme, dossier structure and pricing approach were designed for temperate European markets and are being retrofitted for the Gulf will show it at the first query wave.
Quality Systems Behind Every Sterile Injectable
Farbe Firma fills sterile injectables on ISO Class 5 aseptic lines inside a WHO-GMP certified facility in Gujarat, India. Sterility assurance is engineered rather than assumed: terminal sterilisation or aseptic processing is chosen on the product's own merits and supported by media fill validation, routine environmental and personnel monitoring, container closure integrity testing and a documented contamination control strategy. Release testing runs on HPLC and GC for assay and related substances, LAL for bacterial endotoxins, Karl Fischer for water content where the presentation requires it, and full compendial sterility testing. Because a GCC or Omani reviewer may ask for site-level evidence at any point, the Site Master File, process validation protocols and plant documentation are maintained as living documents rather than assembled in response to a query.
Stability is generated to ICH Q1A(R2) with photostability under ICH Q1B and defended on hot and humid conditions consistent with the GCC stability guidance, in the container-closure system that will actually ship, per presentation. Dossiers are compiled in CTD structure and prepared so that module one can be assembled to eCTD requirements as Oman moves in that direction, and the compendial reference set covers IP, USP, BP and EP. On packaging, artwork is prepared to carry GS1 DataMatrix coding with GTIN, expiry, batch and serial number so that GCC barcoding expectations are met at first print rather than through a variation, and outer packaging is prepared with Arabic translation for products that are not hospital-only, with distinct colour coding across strengths and the reduced-particulars layout for containers of ten millilitres and below.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Oman for Global Buyers
The India-Oman relationship has moved in the exporter's favour and it is worth understanding precisely. Bilateral trade reached about US$10.61 billion in FY 2024-25, up from US$8.94 billion the year before, with India's exports to Oman at roughly US$4.06 billion. Under the Comprehensive Economic Partnership Agreement, Oman granted duty-free access on 98.08% of tariff lines covering 99.38% of India's export value, effective from day one, against a previous position where only 15.33% of India's export value entered duty-free under most-favoured-nation treatment. India's Press Information Bureau records binding zero-duty access for key finished medicines and vaccines and for core active pharmaceutical ingredients including penicillins, streptomycins, tetracyclines and erythromycins, and describes a regulatory chapter covering acceptance of GMP certificates and inspection outcomes, streamlined stability requirements and fast-tracked marketing authorisations. We would add one honest caveat that a careful buyer will appreciate: those regulatory commitments are described in India's summary of the agreement rather than in Omani regulatory guidance, and the fast-track language is tied to approval by named stringent regulators, so they should be confirmed against the Drug Safety Center's own requirements for any specific product.
The clinical demand behind Omani injectable tenders is concentrated in predictable places. Oman's national STEPS survey found adult diabetes prevalence of 15.7%, and the published epidemiology of end-stage kidney disease records the dialysis population rising from 35 patients in 1983 to 2,023 in 2018, a prevalence of about 1,150 per million population. Oman maintains a national cancer registry and the Ministry publishes cancer reports. You can see the same picture in what the Ministry tenders for: it publishes dedicated price lists for renal dialysis items, for respiratory and anaesthesia items, and for pharmaceuticals, vaccines and sera. Diabetes complications, renal replacement therapy, oncology, anaesthesia and critical care are the categories that drive sterile small-volume parenteral demand, and they sit inside a Vision 2040 health direction the Ministry frames as building a leading healthcare system to international standards.
Farbe Firma Pvt Ltd works as both manufacturer and CDMO, which fits a market where the same molecule may need to serve a Ministry of Health tender, a private hospital group and a regional distributor at once. For Oman we support Arabic and English artwork and package inserts prepared to the Drug Safety Center's labelling expectations, GS1 DataMatrix serialisation-ready packaging, CTD-structured dossiers built with eCTD assembly in mind, GCC-aligned hot-and-humid stability packages, and the GMP certificates, Site Master File, process validation protocols, plant and company profiles and per-batch certificates of analysis that a licensed Omani agent needs in order to open a company file and then a product file. Flexible batch sizes mean a distributor is not forced to buy tender-scale quantities for a private-hospital channel. Contract development and manufacturing, own-label supply and technology transfer are all available on the same quality system.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Who regulates medicines and injectables in Oman?
The Drug Safety Center (DSC) of the Ministry of Health. This is the current name under which the Ministry publishes its medicines guidelines, circulars and public consultations, and it supersedes the older Directorate General of Pharmaceutical Affairs and Drug Control naming that still appears in secondary legal commentary. The DSC registers medicinal companies and products through the Ministry's e-portal, with a Technical Committee for Registration and Prices taking the registration decision and approving the price, and it also publishes guidance on pharmacovigilance, bioequivalence, biowaivers, biological products and labelling.
Does Oman require a local agent for a foreign manufacturer?
Yes. The Ministry of Health's published service listing for registering health products requires a pharmaceutical warehouse licence issued by the Directorate of Pharmaceutical Licences, a commercial agency certificate from the Ministry of Commerce and Industry, and a commercial register entry. In practice that means a foreign manufacturer appoints a licensed Omani agent-distributor who holds those licences and submits on the manufacturer's behalf. Separately, the Directorate General of Medical Supplies pre-qualifies companies and factories of medical supplies for Ministry tenders under Ministerial Decision No. 109/2008.
How does GCC central registration affect an Oman submission?
It helps materially. The Gulf Central Committee for Drug Registration registers companies and products under unified GCC regulations, and its mandate includes inspecting manufacturing sites for GMP compliance. In the regulatory framework the Drug Safety Center published for consultation in 2026, products registered through the Gulf Health Council route are placed on a fast-track assessment pathway, and company registrations submitted on the basis of GCC central registration have their validity aligned to the GCC certificate rather than to a separate national clock. The Gulf Health Council also runs a central registration portal and a joint procurement programme.
What are Oman's labelling and barcoding requirements for injectables?
The Drug Safety Center's labelling guideline requires an Arabic translation of outer packaging information for all medicines except those intended solely for hospital use, requires distinct packaging colour codes between different strengths, sets reduced labelling particulars for small immediate containers of ten millilitres or less, and requires in-use, post-reconstitution and post-dilution shelf life statements on the label, the patient leaflet and the summary of product characteristics. On coding, the Gulf Health Council barcoding specification hosted on the Ministry's Drug Safety Center page requires GS1 DataMatrix carrying GTIN, expiry date, batch or lot and a serial number, and applies to international manufacturers exporting to the GCC.
What makes Farbe Firma a suitable injectable manufacturer for Oman?
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Oman we compile CTD-structured dossiers prepared with eCTD assembly in mind, generate ICH Q1A(R2) and Q1B stability data defended on GCC hot-and-humid conditions, prepare Arabic and English artwork to the Drug Safety Center's labelling expectations with GS1 DataMatrix serialisation-ready coding, and supply the GMP certificates, Site Master File, process validation protocols and per-batch certificates of analysis a licensed Omani agent needs to open and defend a file. Contact director@farbefirma.org to discuss a specific molecule, tender or own-label programme.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments